BIX-01294 is an inhibitor of G9a Histone Methyltransferase with IC50 of 1.9 μM. BIX01294 suppresses osteoclast differentiation on mouse macrophage-like Raw264.7 cells. BIX01294 enhances the cardiac potential of bone marrow cells. BIX-01294 (5 µM) reduces levels of global H3K9 methylation in pronuclear- and 2-cell-stage embryos. BIX-01294 (1 µg/mL) causes reduction in the BrdU incorporation of fetal PASMCs. BIX-01294 treatment decreases the PASMCs migration induced by PDGF.
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
|Solubility||DMSO 10 mM|
Modulation of microRNA expression in human lung cancer cells by the G9a histone methyltransferase inhibitor BIX01294.
Pang AL, et al. Oncol Lett. 2014 Jun;7(6):1819-1825. PMID: 24932239.
BIX01294 suppresses osteoclast differentiation on mouse macrophage-like Raw264.7 cells.
Tsuda H, et al. Bosn J Basic Med Sci. 2013 Nov;13(4):271-5. PMID: 24289765.
The histone methyltransferase inhibitor BIX01294 enhances the cardiac potential of bone marrow cells.
Mezentseva NV, et al. Stem Cells Dev. 2013 Feb 15;22(4):654-67. PMID: 22994322.
BIX-01294 treatment blocks cell proliferation, migration and contractility in ovine foetal pulmonary arterial smooth muscle cells.
Yang Q, et al. Cell Prolif. 2012 Aug;45(4):335-44. PMID: 22691107.
|Related Histone Methyltransferase Products|
EPZ011989 is a potent, orally-available EZH2 inhibitor with Ki < 3 nM for EZH2 wt and EZH2 Y646.
SGC0946 is a highly potent and selective DOT1L methyltransferase inhibitor with IC50 of 0.3 nM; selectively kill mixed lineage leukaemia cells.
UNC0642 is a potent, selective inhibitor of histone methyltransferases G9a/GLP with IC50s less than 2.5 nM for G9a and GLP and shows more than 300-fold selective for G9a and GLP over a broad range of kinases, GPCRs, transporters, and ion channels.
JQ-EZ-05 is a specific and reversible EZH1/2 inhibitor.
LLY-283 is the potent and selective SAM-competitive chemical probe for PRMT5. It inhibits PRMT5 enzyme activity with IC50 of 20 nM for methylation of an H4R3 derived peptide substrate, and shows greater than 100-fold selectivity over other histone methyltransferases and non-epigenetic targets.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.